ArticleExperimental and therapeutic medicine2022

Durable response after the discontinuation of pembrolizumab treatment due to an adverse event in a patient with advanced endometrial cancer: A case report.

Shuntaro Umihira et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.